US-Norwegian merger creates Ivax Nycomed
This article was originally published in Clinica
Executive Summary
In a "merger of equals" US-based generics manufacturer Ivax will combine with Norwegian contrast media producer Hafslund Nycomed in a one-to-one stock swap. The new company, Ivax Nycomed, will have a market capitalisation of $6,500 million and revenues of more than $2,500 million a year.